Sullivan Lara 4
4 · Pyxis Oncology, Inc. · Filed Sep 13, 2023
Insider Transaction Report
Form 4
Sullivan Lara
DirectorPresident ,CEO & CMO
Transactions
- Sale
Common Stock
2023-09-13$2.27/sh−3,000$6,816→ 2,597,265 total - Sale
Common Stock
2023-09-11$2.27/sh−20,000$45,414→ 2,605,182 total - Sale
Common Stock
2023-09-12$2.25/sh−4,917$11,071→ 2,600,265 total - Tax Payment
Common Stock
2023-09-13$2.13/sh−184,742$393,500→ 2,412,523 total
Footnotes (5)
- [F1]Reflects sales of common stock executed in multiple transactions. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected within the ranges set forth in footnotes 2 through 4 of this Form 4.
- [F2]The transaction was executed in multiple trades in prices ranging from $2.13 to $2.36.
- [F3]The transaction was executed in multiple trades in prices ranging from $2.21 to $2.30.
- [F4]The transaction was executed in multiple trades in prices ranging from $2.25 to $2.34.
- [F5]Represents shares withheld to cover taxes due upon the vesting of certain restricted stock units.